Patents by Inventor Leah Klapper

Leah Klapper has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Humanized immunomodulatory monoclonal antibodies for the treatment of immunodeficiency
    Patent number: 7981416
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.
    Type: Grant
    Filed: March 18, 2009
    Date of Patent: July 19, 2011
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Peptide useful in immunomodulation
    Patent number: 7745397
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Grant
    Filed: December 14, 2007
    Date of Patent: June 29, 2010
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES FOR THE TREATMENT OF NEOPLASTIC DISEASE OR IMMUNODEFICIENCY
    Publication number: 20090263386
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from an immune deficiency.
    Type: Application
    Filed: March 18, 2009
    Publication date: October 22, 2009
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Human immunomodulatory monoclonal antibodies for the treatment of cancer
    Patent number: 7524498
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Grant
    Filed: September 12, 2007
    Date of Patent: April 28, 2009
    Assignees: CureTech Ltd., Mor-Research Application Ltd.
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • PEPTIDE USEFUL IN IMMUNOMODULATION
    Publication number: 20080175855
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Application
    Filed: December 14, 2007
    Publication date: July 24, 2008
    Applicants: Curetech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
    Patent number: 7332582
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Grant
    Filed: November 19, 2004
    Date of Patent: February 19, 2008
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Steven Tarran Jones, Leah Klapper
  • Peptide useful in immunomodulation
    Patent number: 7329639
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Grant
    Filed: April 27, 2006
    Date of Patent: February 12, 2008
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • HUMANIZED IMMUNOMODULATORY MONOCLONAL ANTIBODIES FOR THE TREATMENT OF NEOPLASTIC DISEASE OR IMMUNODEFICIENCY
    Publication number: 20080025980
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, particularly T cells, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Application
    Filed: September 12, 2007
    Publication date: January 31, 2008
    Applicants: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Steven Jones, Leah Klapper
  • Peptide useful in immunomodulation
    Patent number: 7122372
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Grant
    Filed: April 9, 2004
    Date of Patent: October 17, 2006
    Assignees: CureTech Ltd., Mor-Research Applications Ltd.
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • Peptide useful in immunomodulation
    Publication number: 20060210573
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Application
    Filed: April 27, 2006
    Publication date: September 21, 2006
    Applicants: Curetech Ltd.,, Mor-Research Applications Ltd.,
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper
  • Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
    Publication number: 20050180969
    Abstract: The present invention provides to a humanized monoclonal antibody having immunostimulatory effects. This antibody binds specifically to B lymphoblastoid cells, induces proliferation and activation of peripheral blood lymphocytes, and is capable of eliciting an anti-tumor effect upon administration to subjects suffering from cancer.
    Type: Application
    Filed: November 19, 2004
    Publication date: August 18, 2005
    Inventors: Britta Hardy, Steven Jones, Leah Klapper
  • Peptide useful in immunomodulation
    Publication number: 20050003397
    Abstract: The present invention provides peptides and polynucleotides, and their use for immunomodulation, immunotherapy and vaccine particularly for anti-cancer therapy, and for diagnosis purposes. The immunomodulatory effect includes induction of proliferation and activation of peripheral blood lymphocytes and induction of an anti-tumor effect upon administration of peptides of the invention to subjects suffering from cancer.
    Type: Application
    Filed: April 9, 2004
    Publication date: January 6, 2005
    Inventors: Britta Hardy, Annat Raiter, Leah Klapper